Three Seasons Wealth LLC bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 30,948 shares of the company's stock, valued at approximately $444,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares in the last quarter. Blue Trust Inc. grew its holdings in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares during the period. Sound Income Strategies LLC grew its holdings in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in 10x Genomics in the fourth quarter valued at approximately $52,000. Finally, SRS Capital Advisors Inc. grew its holdings in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on TXG. Leerink Partners downgraded shares of 10x Genomics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $25.00 to $12.00 in a report on Thursday, February 13th. UBS Group decreased their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research note on Thursday. Leerink Partnrs downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Finally, Citigroup decreased their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $19.79.
Check Out Our Latest Stock Analysis on 10x Genomics
10x Genomics Price Performance
NASDAQ:TXG traded up $0.18 during mid-day trading on Monday, reaching $8.48. The stock had a trading volume of 3,178,655 shares, compared to its average volume of 2,266,116. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -5.58 and a beta of 2.01. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $29.37. The stock's 50 day simple moving average is $9.47 and its two-hundred day simple moving average is $13.04.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Sell-side analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.
Insiders Place Their Bets
In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company's stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. This represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by corporate insiders.
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Read More
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
